Current Oncology

Established in 1994, Current Oncology is a peer-reviewed, Canadian based and Internationally distributed journal. Published bi-monthly plus special supplemental issues, Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy to report upon and to review progress in the management of this disease. Current Oncology is published by Multimed Inc.

Current Oncology is indexed/covered in PubMed, EMBASE (Excerpta Medica Database), Scopus, Journal Selector, CrossRef, Index Copernicus, DOAJ (Directory of Open Access Journals), Google Scholar, EMCare, EBSCOhost.com Research Databases, Science Citation Index Expanded (SciSearch), and Journal Citation Reports/Science Edition. Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC), the U.S. National Library of Medicine's digital archive of biomedical and life sciences journal literature. It is also available in the databases of 100 libraries worldwide, and is a participant of the HINARI program.


The information provided on the Current Oncology website is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.

Announcements

 

GIOTRIF® (afatinib) approved by Health Canada for patients with metastatic adenocarcinoma of the lung with activating EGFR mutation

 

On November 6, 2013, Health Canada approved GIOTRIF® (afatinib) a targeted, oral once-daily tyrosine kinase inhibitor and the first irreversible ErbB Family Blocker approved for the treatment of EGFR mutation positive tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s) tablets.

In clinical trials, GIOTRIF® has been shown to offer patients with EGFR mutation positive NSCLC a significant delay in tumour progression,[i] coupled with improvements in their lung cancer related symptoms versus standard chemotherapy.[i]

Dr. Vera Hirsh, GIOTRIF® clinical trial investigator and medical oncologist at Royal Victoria Hospital in Montreal says, “The approval of GIOTRIF® is an exciting advancement because it works differently than other drugs in its class, by irreversibly blocking multiple EGFR pathways involved in tumour growth.”

GIOTRIF®’s unique mode of action enables it to block EGFR (ErbB1) as well as the other relevant members of the ErbB Family. The covalent and, therefore, irreversible binding of GIOTRIF® is unlike other compounds currently on the market which are reversible in that it provides a sustained, selective, and complete ErbB Family Blockade.[i],[ii]

Discovered and developed by Boehringer Ingelheim, GIOTRIF® is the first Health Canada-approved oncology product from the company.

 

References

[i] Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-50.

[ii]  Reid A, Vidal L, Shaw H, do Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007;43:481-9.

 
Posted: 2013-11-25
 

Congratulations to our Deputy Editor – Dr. Phil Gold for winning the 2013 Prix du Québec award!

 

Congratulations to our Deputy Editor – Dr. Phil Gold for winning the 2013 Prix du Québec award! Dr. Gold will be awarded the Wilder-Penfield Prize for his work in the ground-breaking discovery of the carcinoembryonic antigen (CEA).

The CEA was discovered in 1965 by Dr. Gold and his colleague, Samuel Freedman. This discovery revolutionized cancer research and is now the most frequently used blood test in modern oncology. The discovery of the CEA also launched the field of oncodevelopmental biology.

Thank you for your important contribution to oncology, Dr. Gold!

 
Posted: 2013-11-20
 

Meeting/Conference: 18th International Conference on Cancer Nursing (ICCN)

 
The International Society of Nurses in Cancer Care (ISNCC) invites you to the 18th International Conference of Cancer Nursing (ICCN), to be held at the Hilton Panama, Panama City, Panama, from September 7 -11, 2014. The theme for this conference is ‘Strengthening Leadership, Unity and Compassion in Cancer Care. We are anticipating approximately 500 cancer nursing professionals across the globe to attend this conference.

Call for Abstracts

ISNCC is now accepting abstract submissions for oral or poster presentations addressing the conference theme. Abstracts may be submitted in either English or Spanish.  Abstracts submitted in Spanish will be evaluated for Spanish language only concurrent sessions and not for English language concurrent sessions or for poster sessions.  A total of 12 Spanish language abstracts will be accepted. Abstracts will be selected based on the following categories:
 

  1. Administration/Leadership Development
  2. Clinical/Evidence-Based Practice
  3. Education
  4. Research

Click here to download the official call for abstracts announcement.

Abstract Submission Deadline: January 16, 2013 at 3:00 AM ET

For more information on how to submit an abstract, please visit http://www.isncc.org/?page=18ICCN_Abstracts

Registration

Online rregistration is now open. ISNCC is now offering a discounted registration rate for ISNCC individual members. Click here to learn more.

 

ISNCC Member

ISNCC Non Member

Early Registration Rate (Before May 15, 2014)

$695USD

$715USD

Early Registration Deadline: May 15, 2014

Visit http://www.isncc.org/?page=18th_ICCN for conference update.

 
Posted: 2013-11-04
 
More Announcements...

Vol 21, No 3 (2014)


Cover Page

 My Journey with a Blood Disorder

The acrylic painting on the cover of this issue is entitled “My Journey with a Blood Disorder” and is by a person diagnosed with cancer from the 2012 Lilly Oncology On Canvas: Expressions of a Cancer Journey Art Competition and Exhibition.

Oncology On CanvasSM is an art competition and exhibition that honours the journeys people face when confronted with a cancer diagnosis. This biennial competition invites individuals diagnosed with any type of cancer—as well as their families, friends, caregivers and healthcare providers—to express, through art and narrative, the life-affirming changes that give their cancer journeys meaning.

Oncology On Canvas was started in 2004 by Lilly Oncology to help address a great, unmet need in cancer care—a need that goes beyond medicine—to help those affected by cancer cope with the emotional toll of the disease. Since 2004, the National Coalition for Cancer Survivorship (NCCS) has been the co-presenter of the Lilly Oncology On Canvas Art Competition and Exhibition for US and Puerto Rico residents.

This year, Oncology on Canvas comes to Canada. Visit www.lillyocc.com (Lilly Oncology on Canvas Canada) to learn more and download a registration and submission packet. Lilly Oncology On Canvas Canada is presented in partnership with the Canadian Association for Psychosocial Oncology and the Canadian Cancer Survivor Network.

Current Oncology is committed to the Canadian oncology community as well as oncology communities around the world. We are pleased to help raise awareness of this great program created by Lilly. Current Oncology will be selecting new artwork for each cover from previous competitions.

Artwork from the Canadian competition will be viewable at www.lillyocc.com. Artwork from the US competition is available for viewing at www.lillyoncologyoncanvas.com






Copyright © 2014 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)